FINANCIAL STATEMENTS 119 17 PROVISIONS FOR LIABILITIES AND CHARGES Total $m At 1 January 2004 395 Income statement 15 Net amounts paid or becoming current 123 Other movements, including exchange 21 At 31 December 2004 266 Income statement 102 Net amounts paid or becoming current 39 Other movements, including exchange 20 At 31 December 2005 309 Income statement 87 Net amounts paid or becoming current 97 Other movements, including exchange 28 At 31 December 2006 327 Provisions comprise environmental, litigation and other provisions.
Further details of environmental provisions are given in Note 26.
No provision has been released or applied for any purpose other than that for which it was established.
18 STATEMENT OF CHANGES IN EQUITY 2006 2005 2004 $m $m $m Total equity at 1 January 13,691 14,497 13,175 Net profit for the period 6,063 4,724 3,683 Dividends Note21 2,217 1,676 1,408 Transfers from minority interests to payables 6 6 1 Issues of AstraZeneca PLC Ordinary Shares 985 143 102 Repurchase of AstraZeneca PLC Ordinary Shares 4,147 3,001 2,212 Share based payments 129 143 163 Treasury shares 13 11 17 Foreign exchange and other adjustments on consolidation 922 1,052 744 Available for sale losses gains 20 10 31 Actuarial loss 108 35 179 Tax on items taken directly to reserves 137 25 416 Net movement in equity 1,725 806 1,322 Total equity at 31 December 15,416 13,691 14,497 Included in foreign exchange adjustments on consolidation, is a tax credit in 2004 of $357m in respect of foreign exchange loss deductions arising in 2000 see Note 4.
